



# BERYL DRUGS LIMITED

Regd. Off.: Ground Floor, 133, Kanchan Bagh, Indore - 452001 (M.P.)

Tel. : (0731) 2517677 | E-mail : beryldrugs25@yahoo.com | CIN : L02423MP1993PLC007840

Date: 29<sup>th</sup> May, 2023

To,  
The DCS-Listing  
The Bombay Stock Exchange Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

Sub: SUBMISSION OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31<sup>ST</sup> MARCH, 2023 UNDER REGULATION 33 OF THE SECURITIES & EXCHANGE BOARD OF INDIA (LISTING OBLIGATION & DISCLOSURE REQUIREMENTS) REGULATION, 2015

Sir/ Madam,

This is with reference to the above; Please find attached the Audited Financial Results for the year ended 31st March, 2023 as per format prescribed under the regulation 33 of the Securities & Exchange Board of India (Listing Obligation & Disclosure Requirements) Regulation, 2015. Please take the attached Financials on your record.

Kindly take on your record.

Thanking You,

Yours Faithfully,

For Beryl Drugs Limited

Sudhir Sethi  
Chairman & Director  
DIN: 00090172





**BERYL DRUGS LIMITED**  
Gr. Floor, 133, Kanchan Bagh, Indore (M.P.) – 452 001.  
Tel./ Fax 0731-2517677  
E-mail : beryldrugs25@yahoo.com  
CIN : L02423MP1993PLC007840

# ANNEXURE I

## Submission of Audited Financial Result by Companies Other than Banks

Part I					
Statement of standalone Audited Result for the Quarter/ year ended 31/03/2023 (Rs in lakhs)					
Particulars	Quarter ended			Year Ended	
	3 months ended (31-03-2023)	Preceding 3 months ended (31-12-2022)	Corresponding 3 months ended in the previous year (31-03-2022)	Year to date figures for current period ended (31-03-2023)	Year to date figures for previous period ended (31-03-2022)
	Audited	Unaudited	Audited	Audited	Audited
1 Revenue From Operations					
Net sales or Revenue from Operations	611.01	615.45	346.91	2688.78	1460.37
Other operating revenues	-1.69	3.58	5.13	26.87	16.49
<b>Total Revenue from operations (net)</b>	<b>609.33</b>	<b>619.03</b>	<b>352.04</b>	<b>2715.66</b>	<b>1476.86</b>
2 Expenses					
(a) Cost of materials consumed	334.08	370.99	278.82	1422.80	870.72
(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00
(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-10.25	43.30	-39.70	31.25	-30.41
(d) Employee benefit expense	45.08	47.03	28.83	169.68	131.09
(e) Finance costs	6.03	11.74	9.93	41.56	43.68
(f) Depreciation and amortisation expense	15.41	22.01	27.12	81.44	108.65
(g) Other Expenses	212.97	286.19	112.86	870.54	448.16
<b>Total expenses</b>	<b>603.82</b>	<b>781.26</b>	<b>417.86</b>	<b>2617.27</b>	<b>1571.89</b>
3 Profit (loss) from operations before exceptional items and tax	6.51	37.77	-65.82	98.39	-95.03
4 Exceptional items	0.00	0.00	0.00	0.00	0.00
5 Profit (loss) before tax	6.51	37.77	-65.82	98.39	-95.03
6 Tax Expense					
Current tax	1.47	6.25	0.91	16.03	0.91
Deferred tax	-1.78	17.24	-19.29	5.75	-30.04
<b>Total Tax Expenses</b>	<b>-0.31</b>	<b>23.49</b>	<b>-18.38</b>	<b>21.78</b>	<b>-29.13</b>
7 Net Profit (loss) for the period from continuing operations	6.32	14.28	-47.44	76.61	-65.90
8 Net Profit (loss) from discontinuing operations before tax	0.00	0.00	0.00	0.00	0.00
9 Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
10 Net Profit (loss) from discontinuing operations after tax	0.00	0.00	0.00	0.00	0.00
11 <b>Net Profit (loss) for the Period</b>	<b>6.32</b>	<b>14.28</b>	<b>-47.44</b>	<b>76.61</b>	<b>-65.90</b>
12 Other comprehensive income					
(i) Items that will not be reclassified to Statement of Profit and Loss	0.00	0.00	0.00	0.00	0.00
(ii) Items that will be reclassified to Statement of Profit and Loss	-0.25	2.27	2.37	0.67	2.32
13 <b>Total Comprehensive Income</b>	<b>6.07</b>	<b>16.55</b>	<b>-45.07</b>	<b>77.28</b>	<b>-63.58</b>
14 Details of equity share capital					
Paid-up equity share capital	507.170	507.170	507.170	507.170	507.170
Face value of equity share capital	10.000	10.000	10.000	10.000	10.000
15 Earnings per share					
I Basic earnings per share before extraordinary items	0.12	0.28	-0.94	1.52	-1.30
II Diluted earnings per share before extraordinary items	-0.36	0.28	-0.94	1.52	-1.30

- Notes to the Results:**
- The above Financial Results for the quarter and year ended 31<sup>st</sup> March 2023 have been reviewed by the Audit Committee and approved & taken on record by the Board at their Board meeting held on Tuesday 30th May 2022 and the financial result have been audited by the Statutory Auditors of the Company. The statutory Auditors have expressed an unmodified audit opinion on the results.
  - This Statement is as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These audited financial results of the Company are prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (The Act) read with relevant Rules issued thereunder (Ind AS) and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India (SEBI).
  - The figures for the quarter ended March 31, 2023 and the quarter ended March 31, 2022 are the balancing figures between the audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year which were subject to limited review by the Statutory Auditors of the Company.
  - Figures for the previous periods have been regrouped, wherever necessary and minus figures are shown in brackets.
  - Depreciation on fixed assets is provided on written down value method as per the estimated remaining useful life of assets.
  - Revenue from Operations is net of GST.
  - Earnings per share amount is shown in Rupees.
  - The Company has identified "Pharmaceutical Industry" as the single operating segment for the continued operations in the standalone financial statements as per Ind AS 108 "Operating Segments".

For and on behalf of the Board of Directors of  
BERYL DRUGS LIMITED

Sanjay Sethi  
Managing Director  
DIN 00090272

Date: 29<sup>th</sup> May 2023  
Place: Indore

# Beryl Drugs Limited

CIN : L02423MP1993PLC007840

Registered Office : 133, Kanchan Bagh Colony, Indore (M.P.)-452001

## Statement of assets and liabilities as at 31st March 2023

<u>No.</u>	<u>Particulars</u>	<u>As at 31st March</u> <u>2023</u>	<u>As at 31st March</u> <u>2022</u>
<b><u>Asset</u></b>			
<b>A</b>	<b><u>Non-Current Assets</u></b>		
1	Property, Plant and Equipment	581.04	585.95
2	Investment Property	21.39	18.00
3	Other Intangible assets	0.12	0.22
4	<b>Financial assets</b>		
a)	Investments	15.28	15.85
b)	Other Financial Assets	13.14	13.50
5	Deferred Tax Assets (Net)	12.62	18.64
6	Other Non-Current Assets	75.91	77.01
	<b><u>Total Non Current Assets</u></b>	<b><u>719.50</u></b>	<b><u>729.17</u></b>
<b>B</b>	<b><u>Current Assets</u></b>		
1	Inventories	105.46	297.82
2	<b>Financial Assets</b>		
a)	Investments	0.00	0.00
b)	Trade Receivable	690.02	444.85
c)	Cash and cash equivalents	28.31	27.14
d)	Bank balances other than (c) above	29.08	40.02
c)	Loans	1.50	0.00
d)	Other Financial Asstes	98.47	54.61
3	Current Tax Assets (Net)	0.00	3.36
4	Other current assets	78.80	180.75
	<b><u>Total Current Assets</u></b>	<b><u>1031.65</u></b>	<b><u>1048.56</u></b>
<b>C</b>	<b><u>Assets held for Sale</u></b>	<b><u>0.00</u></b>	<b><u>4.66</u></b>
	<b><u>Total Assets</u></b>	<b><u>1751.14</u></b>	<b><u>1782.38</u></b>
<b><u>Equity &amp; Liabilities</u></b>			
<b>A</b>	<b><u>Equity</u></b>		
1	Equity Share Capital	509.37	509.37
2	Other Equity	297.27	219.99
	<b><u>Total Equity</u></b>	<b><u>806.63</u></b>	<b><u>729.36</u></b>



<b>B</b>	<b><u>Non-Current Liabilities</u></b>		
	<b>1 Financial Liabilities</b>		
	a) Borrowings	271.94	167.52
	b) Other Financial Liabilities	0.00	0.00
	<b>2 Provisions</b>	39.69	36.26
	<b><u>Total Non-Current Liabilities</u></b>	<b><u>311.63</u></b>	<b><u>203.78</u></b>
<b>C</b>	<b><u>Current Liabilities</u></b>		
	<b>1 Financial Liabilities</b>		
	a) Borrowings	182.27	361.84
	b) Trade Payables		
	- total outstanding dues of micro enterprises and small enterprises	13.85	49.40
	- total outstanding dues of creditors other than micro enterprises and small enterprises	310.92	256.30
	c) Other Financial Liabilities	42.30	31.84
	<b>2 Other Current Liabilities</b>	73.15	27.82
	<b>3 Provisions</b>	3.82	2.04
	<b>4 Current Tax Liabilities (Net)</b>	6.57	0.00
	<b><u>Total Current Liabilities</u></b>	<b><u>632.88</u></b>	<b><u>729.24</u></b>
<b>D</b>	<b><u>Liabilities held for Sale</u></b>	0.00	120.00
	<b><u>Total Liabilities and Equity</u></b>	<b><u>1751.14</u></b>	<b><u>1782.38</u></b>

For, Beryl Drugs Limited

Sanjay Sethi, Director  
DIN : 00090277



Date : 29/05/2023

Place : Indore


**Beryl Drugs Limited**  
CIN: L02423MP1993PLC007840  
Registered Office: 133, Kanchan Bagh Indore (M.P.)-452001

**Cash Flow Statement for the year ended 31st March 2023**

S. No. Particulars	(Rs. In Lakhs)	
	For the year ended 31st March 2023	For the year ended 31st March 2022
<b>A Cash Flow from Operating Activities</b>		
1 Profit Before Tax	98.39	(95.03)
Add : Depreciation, Amortization and Impairment	81.44	108.65
Add : Finance Cost	41.56	40.58
Less : Rental Income	(12.73)	(12.73)
2 Operating Profit Before Working Capital Changes	208.65	41.47
3 Adjustment for : (Increase) / Decrease in Operating Assets		
Inventories	192.36	(70.92)
Trade Receivables	(245.16)	9.22
Bank Balances other than Cash & Cash Equivalents	10.94	(19.81)
Other Financial Assets	(43.50)	(5.28)
Other Non Current Assets	(2.67)	0.00
Other Current Assets	101.95	17.84
	13.91	(68.94)
Increase/(Decrease) in Operating Liabilities and Provisions		
Provisions	6.72	5.23
Trade Payables	19.08	(4.68)
Other Financial Liabilities	10.46	(20.95)
Other Current Liabilities	(4.67)	4.05
	31.59	(16.35)
4 Cash Flow used in Operations	254.15	(43.83)
Payment of Income Tax	(6.11)	(3.06)
Net Cash Used in Operating Activities (A)	248.04	(46.88)
<b>B Cash Flow from Investing Activities</b>		
1 Purchase of Property Plant and Equipments (PPE)	(156.35)	(41.55)
2 Proceeds from Government Grant in respect of tangible assets	81.17	81.17
3 Capital Advances and Others	3.78	0.05
4 Proceeds from Sale of Investments	0.00	0.00
6 Rental Income	12.73	12.73
7 Payment of Liabilities Held for Sale	(70.00)	0.00
8 Loans Given to Others	(1.50)	0.00
Net Cash Used in Investing Activities (B)	(130.17)	52.40
<b>C Cash Flow from Financing Activities</b>		
1 Changes in Short Term Borrowings	(178.41)	48.10
2 Proceeds from Long Term Borrowings	115.24	167.52
3 Repayment of Long Term Borrowings	(11.99)	(198.63)
4 Finance Costs	(41.56)	(40.58)
Net Cash Used in Financing Activities (C)	(116.71)	(23.59)
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	1.17	(18.07)
Cash and Cash Equivalents at the Beginning of the Year	27.14	45.21
Cash and Cash Equivalents at the End of the Year	28.31	27.14
<b>Components of Cash and Cash Equivalents:</b>		
Cash on Hand	17.52	26.32
Balance with bank in Current Account	1.78	0.82
Fixed Deposit having maturity less than 3 months	9.00	0.00
	28.31	27.14

For and on behalf of the Board of Directors  
Beryl Drugs Limited

Sanjay Sethi  
Managing Director  
DIN : 00090277



Date : 29/05/2023  
Place : Indore



# BERYL DRUGS LIMITED

Regd. Off.: Ground Floor, 133, Kanchan Bagh, Indore - 452001 (M.P.)

Tel. : (0731) 2517677 | E-mail : beryldrugs25@yahoo.com | CIN : L02423MP1993PLC007840

29<sup>th</sup> May, 2023

To,  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
MUMBAI – 400 001

Subject: Submission of declaration as per Second proviso to the Regulation 33(3)(d) of the SEBI (LODR) Regulation, 2015 for the Annual Audited Financial Results for the year ended 31st March, 2023.

Scrip Code: 524606

Dear Sirs,

We hereby submit the following declaration regarding unmodified Auditors Report on the Audited Financial Results/Statements for the year 31st March, 2023 as audited by the Auditors of the Company.

## DECLARATION

Pursuant to the Regulation 33(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015, and amendments made therein vide SEBI Circular No SEBI/LAD-NRO/GN/2016-17 dated 25<sup>th</sup> May, 2016 and further amendment dated 27<sup>th</sup> May, 2016, We, the undersigned do hereby declare that in the Audit Report, accompanying the Annual Audited Financial Statements of M/s Beryl Drugs Limited for the financial year ended on 31.03.2023, the Auditor does not expressed any Modified Opinion(s)/ Audit Qualification(s)/ or other Reservation(s) and accordingly the the statement on impact of audit qualifications is not required to be given.

Kindly take the same on your record.

Thanking You,

Yours Faithfully,

For Beryl Drugs Limited

for Beryl Drugs Limited

  
Sanjay Sethi,  
Managing Director  
DIN: 00090277



  
Ashish Baraskar  
Chief Financial Officer

# **Subhash Chand Jain Anurag & Associates**

## **Chartered Accountants**

104, Archana Apartment, 8-B, Ratlam Kothi, Indore - 452001 (M.P.)

Ph: 2519439, 2527682

Mob No: +91-93021-23882

Email: [scjainca2004@yahoo.com](mailto:scjainca2004@yahoo.com)



**Independent Auditors' Report on the Quarterly and Year to date Audited IND AS Financial Results of Beryl Drugs Limited pursuant to the Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended**

**To,**  
**The Board of Directors,**  
**Beryl Drugs Limited**

**Report on the audit of the IND AS Financial Results**

### **Opinion**

We have audited the accompanying statement of quarterly and year to date IND AS financial results of Beryl Drugs Limited (the "Company") for the quarter and year ended 31 March 2023, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid annual financial results:

- are presented in accordance with the requirements of Regulation 33 and Regulation 52(4) of the Listing Regulations.
- give a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2023.



## **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the IND AS Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Ind AS financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

## **Emphasis of Matter**

1. The company has taken a loan from Kotak Mahindra Bank for Rs. 175 Lakhs on 01/11/2021, for which charge has not been created till date, for such pendency no reason received from management.
2. The Company has send balance confirmation to Debtors and creditors but the confirmation is still pending from them.

Our opinion is not modified in respect of this matter.

## **Management's Responsibilities for the IND AS Financial Results**

The Statement has been prepared on the basis of the IND AS annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records,



relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the IND AS Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to Ind AS financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's



ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

### Other Matters

The statement includes the results for the quarter ended March 31, 2023 and the corresponding quarter ended in the previous year as reported in these financial results, are the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current and previous financial year respectively, which were subject to limited review, as required under the Listing Regulations.

Our opinion is not modified in respect of these matters.

**For Subhash Chand Jain Anurag & Associates**  
**Chartered Accountants**  
**FRN-004733C**



*(Signature)*

**(Akshay Jain)**  
**Partner**

**M. NO. 447487**

**UDIN: 23447487BGUEBP5503**

**Date: 29/05/2023**

**Place: Indore**